MigraineMind research summary
[Pharmacological characteristics and clinical outcomes of Rimegepant (Nurtec<sup>®</sup> ODT), an oral CGRP receptor antagonist for the acute treatment and prevention of migraine].
Nihon Yakurigaku Zasshi | 2026
ReviewSummary
Migraine is a common neurological disorder that causes significant burden on individuals. Current treatments face challenges like contraindications and delayed effectiveness. Rimegepant is a new oral medication approved for acute and preventive migraine treatments. It works as a CGRP receptor antagonist and shows high affinity for the receptor. Nonclinical studies found no vasoconstriction in critical arteries, indicating low cardiovascular risk. Phase 1 studies in healthy adults showed rimegepant's rapid absorption and longer half-life of 10 hours. This supports fast action for acute treatment and sustained efficacy. Unlike existing CGRP monoclonal antibodies, rimegepant is available as an orally disintegrating tablet. Studies confirm its safety and efficacy for acute treatment. Dosing every other day notably reduced monthly migraine days. Overall, rimegepant offers a flexible and effective option for managing migraines. Clinical relevance: This research highlights rimegepant as a promising oral option for migraine treatment.
Key Learning Points
- Migraine is a widespread condition that significantly impacts daily life for many individuals.
- Rimegepant is a new oral medication that can be used for both treating and preventing migraines.
- This medication has a rapid absorption rate and a long half-life, making it effective for acute migraine relief.
- Rimegepant does not cause vasoconstriction in critical arteries, suggesting it has a low risk for cardiovascular issues.
- Dosing rimegepant every other day has been shown to reduce the number of migraine days experienced each month.
Related migraine research topics
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.